Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention

This study tests whether encapsulated rapamycin (eRapa) — a drug that may slow cancer cell growth — can prevent non-muscle-invasive bladder cancer from coming back after surgery. It is designed for people whose early-stage bladder cancer was completely removed but who are at risk for recurrence. **You may be eligible if...** - You are 18 or older - You have early-stage bladder cancer (Ta, Tis, or T1 — meaning it has not grown into the muscle wall) confirmed by biopsy in the past 90 days - All visible tumors have been removed - You have not previously received BCG (a bladder cancer immunotherapy treatment) or rapamycin - You are not on oral corticosteroids - You do not have active infections **You may NOT be eligible if...** - Your bladder cancer has grown into the muscle wall (T2 or higher) - You have another active cancer requiring treatment - You have lymph node involvement or metastatic disease - You are pregnant, breastfeeding, or unwilling to use contraception during the study - You have a history of prior BCG or rapamycin treatment Talk to your doctor to see if this trial is right for you.